A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)
Phase 4
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Adenomatous Polyposis Coli
Both
Adenomatous Polyposis Coli
Trial Information
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)
Inclusion Criteria:
- Males or females at least 18 years of age with familial adenomatous polyposis.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Measure:
Number and average size of rectal polyps
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Merck
Authority:
Canada: Health Canada
Study ID:
2005_052
NCT ID:
NCT00140894
Start Date:
March 2003
Completion Date:
Related Keywords:
- Adenomatous Polyposis Coli
- Osteoarthritis
- Cancer Pain
- Adenomatous Polyposis Coli
Name | Location |
|---|
